Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

161. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L CRD summary The authors concluded that indirect treatment comparisons (...) indicated teriparatide, zoledronic acid and denosumab had the highest probabilities of being most efficacious for non-vertebral and vertebral fractures. In the absence of direct comparisons, the evidence presented may be the best available. However, the authors' conclusions should be considered tentative given limitations of the evidence and synthesis. Authors' objectives To compare the efficacy of nine osteoporosis medications for reducing fractures in post-menopausal women. Searching Seven databases

DARE.2011

163. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy

Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Pham AN, Datta SK, Weber TJ, Walter LC, Colon-Emeric CS Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to explore the cost-effectiveness of oral bisphosphonate treatment for osteoporosis in women aged 50 to 90 with varying life expectancy. The authors concluded that treatment of women for osteoporosis with oral bisphosphonates was cost-effective regardless of life expectancy

NHS Economic Evaluation Database.2011

164. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled (...) of monthly oral 150mg ibandronate to daily or monthly bisphosphonate or placebo in women with postmenopausal osteoporosis. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to June 2010. Search terms were reported. Bibliographies of selected articles were handsearched. Study selection Randomised controlled trials (RCTs) that compared monthly oral 150mg ibandronate with daily or monthly bisphosphonate or placebo in women with postmenopausal

DARE.2011

165. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis

Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K, Goeree R, Tarride JE, Xie F CRD summary This review (...) Register of Controlled Trials (CENTRAL) were searched until February 2010 without language restrictions (search terms were reported). Bibliographies of reviews identified through the search were handsearched to locate further studies. Study selection Eligible for inclusion were randomised controlled trials (RCTs) that compared the efficacy and safety/tolerability of denosumab versus placebo for treatment of low bone mineral density or osteoporosis in postmenopausal women. The efficacy-related outcome

DARE.2011

166. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cotte FE, De Pouvourville G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of osteoporosis treatment with oral bisphosphonates focusing on the issue of poor persistence in post-menopausal women. The authors concluded that improving persistence with oral bisphosphonate was likely to improve health benefits and reduce costs compared to current levels of treatment adherence

NHS Economic Evaluation Database.2011

167. The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands

The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from (...) as a first-line treatment for the secondary prevention of fragility fractures in women with postmenopausal osteoporosis. The authors concluded that their analysis suggested that zoledronic acid was a cost-effective first-line option. The study methodology was adequate, but limited reporting on key evidence means that it is unclear if the authors' conclusions are appropriate. Type of economic evaluation Cost-utility analysis Study objective The study assessed the cost-effectiveness of zoledronic acid 5mg

NHS Economic Evaluation Database.2011

170. Osteoporosis: Screening

Osteoporosis: Screening Final Update Summary: Osteoporosis: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Osteoporosis: Screening Release Date: January 2011 This topic is in the process of being updated. Please go to the section to see the latest documents available. Recommendation Summary Population Recommendation Grade Women, 65 and Older The USPSTF recommends screening (...) for osteoporosis in women aged 65 years and older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors. Men The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men. ( ) Related Information for Consumers There is no related information for consumers. Related Information for Health Professionals Supporting Documents ( ) ( ) Clinical Summary

U.S. Preventive Services Task Force2011

171. Bisphosphonates for Osteoporosis.

Bisphosphonates for Osteoporosis. Bisphosphonates for osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21083387 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Nov 18;363(21):2027-35. doi: 10.1056/NEJMct1004903. Bisphosphonates for osteoporosis. 1 . 1 Department of Medicine, University of Chicago, Chicago, IL 60637, USA. mfavus@medicine.bsd.uchicago.edu Comment in [N Engl J Med. 2011] [N Engl J Med. 2011] PMID: 21083387 DOI: [Indexed for MEDLINE] Publication type MeSH terms Substances Full Text Sources Other Literature Sources

NEJM2010

172. Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial

Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial 20937977 2010 10 26 2010 11 16 2014 11 20 1524-4539 122 17 2010 Oct 26 Circulation Circulation Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. 1716-24 10.1161/CIRCULATIONAHA (...) CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk. In this study, 8556 women 59 to 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. Cardiovascular events, including major CHD events, were prespecified secondary end points. Compared with placebo, lasofoxifene 0.5 mg/d reduced the risk of major CHD events 32% (hazard ratio, 0.68; 95% confidence interval, 0.50

EvidenceUpdates2010

173. Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention

Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention | Medical Journal of Australia Search form Search Articles Topics MJA team Author centre Multimedia Centenary Place an ad secondlevel Position statement Treatment for osteoporosis in Australian residential aged care facilities: consensus (...) the opportunity to maximise adherence to medication regimens. , Osteoporosis treatment is a particularly challenging area in RACFs. Most residents are at high risk of suffering a fracture, but only a minority receive treatment according to their level of risk. - The Consensus Conference on Treatment of Osteoporosis in RACFs in Australia (Consensus Conference), held in Sydney in July 2009, aimed to deal with some problems of treatment of older residents with osteoporosis in RACFs ( ). In this statement, we

MJA Clinical Guidelines2010

174. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada

Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada 20624868 2010 09 08 2010 09 27 2014 12 03 1488-2329 182 12 2010 Sep 07 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. E610-8 10.1503/cmaj.080663 Hanley David A DA Departments of Medicine, University of Calgary, Calgary, AB, Canada. dahanley@ucalgary.ca (...) Cranney Ann A Jones Glenville G Whiting Susan J SJ Leslie William D WD Cole David E C DE Atkinson Stephanie A SA Josse Robert G RG Feldman Sidney S Kline Gregory A GA Rosen Cheryl C Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada eng Journal Article Practice Guideline Research Support, Non-U.S. Gov't Review 2010 07 12 Canada CMAJ 9711805 0820-3946 1406-16-2 Vitamin D 64719-49-9 25-hydroxyvitamin D AIM IM Lancet. 2007 Aug 25;370(9588):657-66 17720017 J Natl Cancer Inst

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

176. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.

Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:007503 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline

American College of Preventive Medicine2010

178. Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation

Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C. Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 77. 2010 Authors' objectives To determine the effectiveness and harms of osteoporosis screening in reducing fractures for men

Health Technology Assessment (HTA) Database.2010

179. A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis

A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis Lai P, Chua SS, Chan SP CRD summary The authors concluded that non-drug interventions in postmenopausal women (...) with osteoporosis improved quality of life, medication compliance and calcium intake. Further studies were needed on other outcomes. Heterogeneity between the included studies, the small number of studies for each outcome and the low quality of some studies, the authors' conclusions should be treated with caution. Authors' objectives To assess the impact of non-drug interventions by healthcare professionals on community dwelling postmenopausal women with osteoporosis. Searching PubMed, Web of Science, EBMR

DARE.2010